Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
Liancheng FanYan YangChenfei ChiXiaowei MaRui WangYiming GongHongying ZhengJiahua PanYinjie ZhuBaijun DongWei XuePublished in: The Prostate (2019)
Elevated pretreatment serum NED markers might indicate mCRPC patients would get better clinical outcomes from DP-AA than AA-DP. In contrast, those without NED marker elevation had similar outcomes regardless of which agent was chosen first. mCRPC patients with elevated NED markers and chemotherapy response were more inclined to obtain NED markers decline during DP therapy, which could account for this phenomenon.
Keyphrases
- end stage renal disease
- small cell lung cancer
- newly diagnosed
- ejection fraction
- squamous cell carcinoma
- magnetic resonance
- chronic kidney disease
- type diabetes
- magnetic resonance imaging
- metabolic syndrome
- radiation therapy
- patient reported outcomes
- peritoneal dialysis
- bone marrow
- mesenchymal stem cells
- rectal cancer
- amino acid
- weight loss
- smoking cessation